Is Syndax Pharmaceuticals Stock a Good Investment?
Syndax Pharmaceuticals Investment Advice | SNDX |
- Examine Syndax Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Syndax Pharmaceuticals' leadership team and their track record. Good management can help Syndax Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Syndax Pharmaceuticals' business and its evolving consumer preferences.
- Compare Syndax Pharmaceuticals' performance and market position to its competitors. Analyze how Syndax Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Syndax Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Syndax Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Syndax Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Syndax Pharmaceuticals is a good investment.
Sell | Buy |
Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Syndax Pharmaceuticals Stock
Researching Syndax Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 3.36. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.72. The entity had not issued any dividends in recent years.
To determine if Syndax Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Syndax Pharmaceuticals' research are outlined below:
| Syndax Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 23.68 M. Net Loss for the year was (318.76 M) with loss before overhead, payroll, taxes, and interest of (218.79 M). | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (274.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Simplify Asset Management Inc. Buys 25,456 Shares of Syndax Pharmaceuticals, Inc. - MarketBeat |
Syndax Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Syndax Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Syndax Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Syndax Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Syndax Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2019-11-07 | 2019-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2016-08-09 | 2016-06-30 | -0.53 | -0.47 | 0.06 | 11 | ||
2018-11-05 | 2018-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2016-11-10 | 2016-09-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2023-08-03 | 2023-06-30 | -0.73 | -0.64 | 0.09 | 12 | ||
2024-08-01 | 2024-06-30 | -0.91 | -0.8 | 0.11 | 12 | ||
2021-05-11 | 2021-03-31 | -0.65 | -0.54 | 0.11 | 16 |
Know Syndax Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syndax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syndax Pharmaceuticals backward and forwards among themselves. Syndax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syndax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kingdon Capital Management Llc | 2024-12-31 | 2 M | Geode Capital Management, Llc | 2024-12-31 | 2 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.9 M | Woodline Partners Lp | 2024-12-31 | 1.9 M | Franklin Resources Inc | 2024-12-31 | 1.8 M | Avidity Partners Management Lp | 2024-12-31 | 1.5 M | Sphera Funds Management Ltd. | 2024-12-31 | 1.4 M | Silverarc Capital Management, Llc | 2024-12-31 | 1.2 M | Eventide Asset Management, Llc | 2024-12-31 | 1.2 M | Blackrock Inc | 2024-12-31 | 9 M | Kynam Capital Management, Lp | 2024-12-31 | 8.5 M |
Syndax Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.18 B.Market Cap |
|
Syndax Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (1.11) | (1.05) |
Determining Syndax Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Syndax Pharmaceuticals is a good buy. For example, gross profit margin measures Syndax Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Syndax Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Evaluate Syndax Pharmaceuticals' management efficiency
Syndax Pharmaceuticals has return on total asset (ROA) of (0.3174) % which means that it has lost $0.3174 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7569) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2025. Return On Capital Employed is likely to drop to -0.57 in 2025. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 127.8 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 206.2 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.37 | 3.54 | |
| Tangible Book Value Per Share | 3.37 | 3.54 | |
| Enterprise Value Over EBITDA | (3.15) | (3.30) | |
| Price Book Value Ratio | 3.92 | 4.12 | |
| Enterprise Value Multiple | (3.15) | (3.30) | |
| Price Fair Value | 3.92 | 4.12 | |
| Enterprise Value | 987.5 M | 533.4 M |
Management at Syndax Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.923 |
Basic technical analysis of Syndax Stock
As of the 26th of March, Syndax Pharmaceuticals has the Semi Deviation of 2.96, coefficient of variation of 11203.77, and Risk Adjusted Performance of 0.0149. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syndax Pharmaceuticals, as well as the relationship between them.Syndax Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Syndax Pharmaceuticals' Outstanding Corporate Bonds
Syndax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syndax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syndax bonds can be classified according to their maturity, which is the date when Syndax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| SNV 5625 15 FEB 28 Corp BondUS87164DVJ61 | View | |
| SYNCHRONY FINL 45 Corp BondUS87165BAG86 | View | |
| SYNCHRONY FINL 395 Corp BondUS87165BAM54 | View | |
| SYNCHRONY FINL 37 Corp BondUS87165BAL71 | View | |
| SYF 4875 13 JUN 25 Corp BondUS87165BAS25 | View | |
| SYF 2875 28 OCT 31 Corp BondUS87165BAR42 | View | |
| SYF 725 02 FEB 33 Corp BondUS87165BAU70 | View |
Understand Syndax Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Syndax Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0149 | |||
| Market Risk Adjusted Performance | 0.0349 | |||
| Mean Deviation | 2.39 | |||
| Semi Deviation | 2.96 | |||
| Downside Deviation | 3.01 | |||
| Coefficient Of Variation | 11203.77 | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.17 | |||
| Information Ratio | 0.0049 | |||
| Jensen Alpha | 0.0164 | |||
| Total Risk Alpha | 0.0078 | |||
| Sortino Ratio | 0.0052 | |||
| Treynor Ratio | 0.0249 | |||
| Maximum Drawdown | 15.51 | |||
| Value At Risk | (5.07) | |||
| Potential Upside | 6.51 | |||
| Downside Variance | 9.06 | |||
| Semi Variance | 8.76 | |||
| Expected Short fall | (2.49) | |||
| Skewness | 0.4068 | |||
| Kurtosis | 0.7556 |
| Risk Adjusted Performance | 0.0149 | |||
| Market Risk Adjusted Performance | 0.0349 | |||
| Mean Deviation | 2.39 | |||
| Semi Deviation | 2.96 | |||
| Downside Deviation | 3.01 | |||
| Coefficient Of Variation | 11203.77 | |||
| Standard Deviation | 3.19 | |||
| Variance | 10.17 | |||
| Information Ratio | 0.0049 | |||
| Jensen Alpha | 0.0164 | |||
| Total Risk Alpha | 0.0078 | |||
| Sortino Ratio | 0.0052 | |||
| Treynor Ratio | 0.0249 | |||
| Maximum Drawdown | 15.51 | |||
| Value At Risk | (5.07) | |||
| Potential Upside | 6.51 | |||
| Downside Variance | 9.06 | |||
| Semi Variance | 8.76 | |||
| Expected Short fall | (2.49) | |||
| Skewness | 0.4068 | |||
| Kurtosis | 0.7556 |
Consider Syndax Pharmaceuticals' intraday indicators
Syndax Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Syndax Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 31736.0 | |||
| Daily Balance Of Power | (0.54) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 13.5 | |||
| Day Typical Price | 13.48 | |||
| Price Action Indicator | (0.21) | |||
| Period Momentum Indicator | (0.29) | |||
| Relative Strength Index | 43.74 |
Syndax Pharmaceuticals Corporate Filings
F4 | 17th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 7th of March 2025 Other Reports | ViewVerify | |
| 4th of March 2025 Other Reports | ViewVerify | |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Syndax Stock media impact
Far too much social signal, news, headlines, and media speculation about Syndax Pharmaceuticals that are available to investors today. That information is available publicly through Syndax media outlets and privately through word of mouth or via Syndax internal channels. However, regardless of the origin, that massive amount of Syndax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syndax Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syndax Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syndax Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syndax Pharmaceuticals alpha.
Syndax Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Historical Investor Sentiment
Investor biases related to Syndax Pharmaceuticals' public news can be used to forecast risks associated with an investment in Syndax. The trend in average sentiment can be used to explain how an investor holding Syndax can time the market purely based on public headlines and social activities around Syndax Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Syndax Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Syndax Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Syndax Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Syndax Pharmaceuticals.
Syndax Pharmaceuticals Corporate Management
| Briggs MD | Head Pres | Profile | |
| Steven Closter | Chief Officer | Profile | |
| Michael MBA | CEO Director | Profile | |
| Steve Sabus | Chief Officer | Profile | |
| Joseph MD | Member Officer | Profile | |
| Ronald Evans | Advisor CoFounder | Profile | |
| Sharon Klahre | Vice Communications | Profile |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.